Solving the data conundrum in drug discovery
Life sciences companies are spending more on R&D but are earning less for their efforts. However, dealing with more data does not have to mean reduced productivity. Discover why companies that invest in in silico tools have a 50% higher probability of technical success in Phase ll, at a cost reduction of 30% per new medical entity.
Learn more (PDF, 1.5mb)